A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First-in-Human Study Evaluating Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Orally Administered BMS-986521 in Healthy Adult Participants
Latest Information Update: 12 Jan 2026
At a glance
- Drugs BMS 986521 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 07 Jan 2026 Status changed from not yet recruiting to recruiting.
- 23 Dec 2025 New trial record